Cells 2013, 2(1), 19-42; doi:10.3390/cells2010019
Article

CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization

Rebecca J. Platt 1 email, Tansi Khodai 2 email, Tim J. Townend 1 email, Helen H. Bright 2 email, Paul Cockle 3 email, Luis Perez-Tosar 1 email, Rob Webster 1 email, Brian Champion 3 email, Timothy P. Hickling 1,†,* email and Fareed Mirza 1 email
1 Biotherapeutics and Translational Research, Pharmacokinetics, Dynamics & Metabolism, Pfizer Global Research and Development, Sandwich, Kent, CT13-9NJ, UK 2 New Opportunities Unit, Pfizer Global Research and Development, Sandwich, Kent, CT13 -9NJ, UK 3 Vaccine Research Unit, Pfizer Global Research and Development, Sandwich, Kent, CT13-9NJ, UK † Biotherapeutics and Translational Research, Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc, One Burtt Road, Andover, MA 01810, USA.
* Author to whom correspondence should be addressed.
Received: 19 October 2012; in revised form: 22 November 2012 / Accepted: 27 December 2012 / Published: 4 January 2013
(This article belongs to the Special Issue ELISPOT Research)
PDF Full-text Download PDF Full-Text [716 KB, uploaded 4 January 2013 11:30 CET]
Abstract: CD8+ T cells have the potential to control HSV-2 infection. However, limited information has been available on CD8+ T cell epitopes or the functionality of antigen specific T cells during infection or following immunization with experimental vaccines. Peptide panels from HSV-2 proteins ICP27, VP22 and VP13/14 were selected from in silico predictions of binding to human HLA-A*0201 and mouse H-2Kd, Ld and Dd molecules. Nine previously uncharacterized CD8+ T cell epitopes were identified from HSV-2 infected BALB/c mice. HSV-2 specific peptide sequences stabilized HLA-A*02 surface expression with intermediate or high affinity binding. Peptide specific CD8+ human T cell lines from peripheral blood lymphocytes were generated from a HLA-A*02+ donor. High frequencies of peptide specific CD8+ T cell responses were elicited in mice by DNA vaccination with ICP27, VP22 and VP13/14, as demonstrated by CD107a mobilization. Vaccine driven T cell responses displayed a more focused immune response than those induced by viral infection. Furthermore, vaccination with ICP27 reduced viral shedding and reduced the clinical impact of disease. In conclusion, this study describes novel HSV-2 epitopes eliciting strong CD8+ T cell responses that may facilitate epitope based vaccine design and aid immunomonitoring of antigen specific T cell frequencies in preclinical and clinical settings.
Keywords: HSV-2; CD8+ epitope; vaccine; infection

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Platt, R.J.; Khodai, T.; Townend, T.J.; Bright, H.H.; Cockle, P.; Perez-Tosar, L.; Webster, R.; Champion, B.; Hickling, T.P.; Mirza, F. CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization. Cells 2013, 2, 19-42.

AMA Style

Platt RJ, Khodai T, Townend TJ, Bright HH, Cockle P, Perez-Tosar L, Webster R, Champion B, Hickling TP, Mirza F. CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization. Cells. 2013; 2(1):19-42.

Chicago/Turabian Style

Platt, Rebecca J.; Khodai, Tansi; Townend, Tim J.; Bright, Helen H.; Cockle, Paul; Perez-Tosar, Luis; Webster, Rob; Champion, Brian; Hickling, Timothy P.; Mirza, Fareed. 2013. "CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization." Cells 2, no. 1: 19-42.

Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert